[Taylor&Francis] Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy? Closed
|
Reward30points
|
post
reply
points
3081
30
China＊s Government Venture Capital Guidance Funds and Different Types of Innovation: Spillover Effect and Action Mechanism
30
Persistence of jump-induced tail risk and limits to arbitrage
30
Investigating students＊ scientific thinking process during online inquiry learning: a process mining approach
30
Taken to the extreme: Transformational leadership, psychological capital, and follower health outcomes in extreme contexts
30
Taken to the extreme: Transformational leadership, psychological capital, and follower health outcomes in extreme contexts
